Figure 1. Study Flow.

Patients who underwent the intended duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents without any clinical events within 6 to 18 months were enrolled and underwent randomization. A primary composite end point of all-cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding at 24-month follow-up was analyzed in the intention-to-treat population stratified by the presence of diabetes at baseline. PCI indicates percutaneous coronary intervention.